Publications searcher

The science produced by our scientists is very important. In 2022, 1,629 papers were published in scientific journals with a global impact factor of over 15,000 points.

Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory Small Cell Lung Cancer.

PMID: 31260835
Journal: Journal of Thoracic Oncology
Year: 2019
Reference: J Thorac Oncol. 2019 Oct;14(10):1828-1838. doi: 10.1016/j.jtho.2019.06.021. Epub 2019 Jun 28.
Impact factor: 12.46
Publication type: Paper in international publication
Authors: Dhar, Arindam, Govindan, Ramaswamy, Ballas, Marc S, Mohammad, Helai P, Collingwood, Therese, Bauer, Todd M, Besse, Benjamin, Martinez-Marti, Alex, Trigo, Jose Manuel, Moreno, Victor et al.
DOI: 10.1016/j.jtho.2019.06.021

Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory Small Cell Lung Cancer.

PMID: 31260835
Journal: Journal of Thoracic Oncology
Year: 2019
Reference: J Thorac Oncol. 2019 Oct;14(10):1828-1838. doi: 10.1016/j.jtho.2019.06.021. Epub 2019 Jun 28.
Impact factor:
Publication type: Paper in international publication
Authors: Ballas, Marc S; Bauer, Todd M; Besse, Benjamin; Collingwood, Therese; Dhar, Arindam; Ferron-Brady, Geraldine; Garrido, Pilar; Govindan, Ramaswamy; Kruger, Ryan G; Martinez-Marti, Alex et al.
DOI: 10.1016/j.jtho.2019.06.021

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

PMID: 30624604
Journal: ANNALS OF ONCOLOGY
Year: 2019
Reference: Ann Oncol. 2019 Jun 1;30(6):1020. doi: 10.1093/annonc/mdy532.
Impact factor: 14.196
Publication type: Letter or abstract
Authors: Andreis, D De, Ropert, S, Lopez, E, Catteau, A, James, J, Marier, J-F, Beliveau, M, Martell, R E, Baselga, J, Armand, J-P et al.
DOI: 10.1093/annonc/mdy532

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

PMID: 30624604
Journal: ANNALS OF ONCOLOGY
Year: 2019
Reference: Ann Oncol. 2019 Jun 1;30(6):1020. doi: 10.1093/annonc/mdy532.
Impact factor:
Publication type: Letter or abstract
Authors: Andreis, D De; Armand, J-P; Baselga, J; Beliveau, M; Catteau, A; Cortes, J; James, J; Lopez, E; Marier, J-F; Martell, R E et al.
DOI: 10.1093/annonc/mdy532

Phase I study of rapid alternation of sunitinib and regorafenib for the treatment of tyrosine-kinase inhibitor refractory gastrointestinal stromal tumors.

PMID: 31471313
Journal: CLINICAL CANCER RESEARCH
Year: 2019
Reference: Clin Cancer Res. 2019 Dec 15;25(24):7287-7293. doi: 10.1158/1078-0432.CCR-19-2150. Epub 2019 Aug 30.
Impact factor: 8.911
Publication type: Paper in international publication
Authors: Barysauskas, Constance M, Phallen, Jillian, Triplett, Olivia, Marino-Enriquez, Adrian, Wagner, Andrew J, Demetri, George D, Velculescu, Victor E, Paweletz, Cloud P, Fletcher, Jonathan A, George, Suzanne et al.
DOI: 10.1158/1078-0432.CCR-19-2150

Phase I study of rapid alternation of sunitinib and regorafenib for the treatment of tyrosine-kinase inhibitor refractory gastrointestinal stromal tumors.

PMID: 31471313
Journal: CLINICAL CANCER RESEARCH
Year: 2019
Reference: Clin Cancer Res. 2019 Dec 15;25(24):7287-7293. doi: 10.1158/1078-0432.CCR-19-2150. Epub 2019 Aug 30.
Impact factor:
Publication type: Paper in international publication
Authors: Barysauskas, Constance M; Demetri, George D; Fletcher, Jonathan A; George, Suzanne; Kuang, Yanan; Leal, Alessandro; Marino-Enriquez, Adrian; Morgan, Jeffrey A; Paweletz, Cloud P; Phallen, Jillian et al.
DOI: 10.1158/1078-0432.CCR-19-2150

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.

PMID: 30770348
Journal: CLINICAL CANCER RESEARCH
Year: 2019
Reference: Clin Cancer Res. 2019 Jun 1;25(11):3220-3228. doi: 10.1158/1078-0432.CCR-18-2740. Epub 2019 Feb 15.
Impact factor: 8.911
Publication type: Paper in international publication
Authors: Jung, Kyung Hae, LoRusso, Patricia M, Burris, Howard A, Gordon, Michael S, Bang, Yung-Jue, Hellmann, Matthew D, Cervantes, Andres, Ochoa de Olza, Maria, Marabelle, Aurelien, Hodi, F Stephen et al.
DOI: 10.1158/1078-0432.CCR-18-2740

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.

PMID: 30770348
Journal: CLINICAL CANCER RESEARCH
Year: 2019
Reference: Clin Cancer Res. 2019 Jun 1;25(11):3220-3228. doi: 10.1158/1078-0432.CCR-18-2740. Epub 2019 Feb 15.
Impact factor:
Publication type: Paper in international publication
Authors: Ahn, Myung-Ju; Bang, Yung-Jue; Barlesi, Fabrice; Burris, Howard A; Calvo, Emiliano; Cervantes, Andres; Davis, S Lindsey; Emens, Leisha A; Gordon, Michael S; Hamid, Omid et al.
DOI: 10.1158/1078-0432.CCR-18-2740

Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.

PMID: 30679100
Journal: Clinical Breast Cancer
Year: 2019
Reference: Clin Breast Cancer. 2019 Apr;19(2):105-112. doi: 10.1016/j.clbc.2018.12.012. Epub 2018 Dec 20.
Impact factor: 2.762
Publication type: Paper in international publication
Authors: Ortega, Vanesa, Anton, Antonio, Garau, Isabel, Afonso, Noemia, Calvo, Lourdes, Fernandez, Yolanda, Martinez-Garcia, Maria, Blanco, Esperanza, Zamora, Pilar, Garcia, Mirta et al.
DOI: 10.1016/j.clbc.2018.12.012

Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.

PMID: 30679100
Journal: Clinical Breast Cancer
Year: 2019
Reference: Clin Breast Cancer. 2019 Apr;19(2):105-112. doi: 10.1016/j.clbc.2018.12.012. Epub 2018 Dec 20.
Impact factor:
Publication type: Paper in international publication
Authors: Afonso, Noemia; Aguirre, Elena; Anton, Antonio; Blanco, Esperanza; Calvo, Lourdes; Cortes, Javier; Fernandez, Yolanda; Garau, Isabel; Garcia, Mirta; Illarramendi, Jose Juan et al.
DOI: 10.1016/j.clbc.2018.12.012

Phase II randomized study of radiotherapy and three-year androgen deprivation with or without concurrent weekly docetaxel in high-risk localized prostate cancer patients.

PMID: 30321689
Journal: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
Year: 2019
Reference: Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):344-352. doi: 10.1016/j.ijrobp.2018.10.005. Epub 2018 Oct 12.
Impact factor: 6.203
Publication type: Paper in international publication
Authors: Mendez, Ma Jose, Maroto, Pablo, Luque, Raquel, de Portugal, Teresa, Aldabo, Ramon, Bonfill, Teresa, Morales-Barrera, Rafael, Garcia, Jose, Macia, Sonia, Maldonado, Xavier et al.
DOI: 10.1016/j.ijrobp.2018.10.005

Phase II randomized study of radiotherapy and three-year androgen deprivation with or without concurrent weekly docetaxel in high-risk localized prostate cancer patients.

PMID: 30321689
Journal: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
Year: 2019
Reference: Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):344-352. doi: 10.1016/j.ijrobp.2018.10.005. Epub 2018 Oct 12.
Impact factor:
Publication type: Paper in international publication
Authors: Aldabo, Ramon; Bellmunt, Joaquim; Bonfill, Teresa; Carles, Joan; de Portugal, Teresa; Domenech, Montserrat; Figols, Mariona; Font, Albert; Foro, Palmira; Gallardo, Enrique et al.
DOI: 10.1016/j.ijrobp.2018.10.005

Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR study.

PMID: 29794066
Journal: ONCOLOGIST
Year: 2019
Reference: Oncologist. 2019 Jan;24(1):38-46. doi: 10.1634/theoncologist.2017-0622. Epub 2018 May 23.
Impact factor: 5.252
Publication type: Paper in international publication
Authors: Capdevila, Jaume, Teule, Alexandre, Barriuso, Jorge, Castellano, Daniel, Lopez, Carlos, Manzano, Jose Luis, Alonso, Vicente, Garcia-Carbonero, Rocio, Dotor, Emma, Matos, Ignacio et al.
DOI: 10.1634/theoncologist.2017-0622

Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR study.

PMID: 29794066
Journal: ONCOLOGIST
Year: 2019
Reference: Oncologist. 2019 Jan;24(1):38-46. doi: 10.1634/theoncologist.2017-0622. Epub 2018 May 23.
Impact factor:
Publication type: Paper in international publication
Authors: Alonso, Vicente; Barriuso, Jorge; Capdevila, Jaume; Casanovas, Oriol; Castellano, Daniel; Custodio, Ana; Dotor, Emma; Garcia-Carbonero, Rocio; Lopez, Carlos; Manzano, Jose Luis et al.
DOI: 10.1634/theoncologist.2017-0622

Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.

PMID: 30840064
Journal: ANNALS OF ONCOLOGY
Year: 2019
Reference: Ann Oncol. 2019 May 1;30(5):796-803. doi: 10.1093/annonc/mdz082.
Impact factor: 14.196
Publication type: Paper in international publication
Authors: Robles-Diaz, L, Garcia-Alfonso, P, Buges, C, Duran, G, Salud, A, Navarro, V, Capella, G, Salazar, R, Aranda, E, Valladares, M et al.
DOI: 10.1093/annonc/mdz082

Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.

PMID: 30840064
Journal: ANNALS OF ONCOLOGY
Year: 2019
Reference: Ann Oncol. 2019 May 1;30(5):796-803. doi: 10.1093/annonc/mdz082.
Impact factor:
Publication type: Paper in international publication
Authors: Aranda, E; Azuara, D; Buges, C; Capella, G; Duran, G; Elez, E; Falco, E; Garcia-Alfonso, P; Lopez-Lopez, C; Navarro, V et al.
DOI: 10.1093/annonc/mdz082

Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide.

PMID: 30523748
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2019
Reference: J Clin Oncol. 2019 Feb 10;37(5):367-374. doi: 10.1200/JCO.18.00053. Epub 2018 Dec 4.
Impact factor: 28.245
Publication type: Paper in international publication
Authors: Wease, Stephen, Blackwell, Beth, Valcarcel, David, Frassoni, Francesco, Boelens, Jaap Jan, Nierkens, Stefan, Jagasia, Madan, Wagner, John E, Kuball, Jurgen, Koh, Liang Piu et al.
DOI: 10.1200/JCO.18.00053

Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide.

PMID: 30523748
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2019
Reference: J Clin Oncol. 2019 Feb 10;37(5):367-374. doi: 10.1200/JCO.18.00053. Epub 2018 Dec 4.
Impact factor:
Publication type: Paper in international publication
Authors: Blackwell, Beth; Boelens, Jaap Jan; Cilloni, Daniela; Frassoni, Francesco; Freedman, Laurence S; Hanna, Rabi; Horwitz, Mitchell E; Hwang, William Y K; Jagasia, Madan; Koh, Liang Piu et al.
DOI: 10.1200/JCO.18.00053

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

PMID: 30624616
Journal: ANNALS OF ONCOLOGY
Year: 2019
Reference: Ann Oncol. 2019 Jun 1;30(6):1017. doi: 10.1093/annonc/mdy529.
Impact factor: 14.196
Publication type: Letter or abstract
Authors: Baselga, J, Manikhas, A, Cortes, J, Roman, L, Semiglazov, V F, Byakhov, M, Lokanatha, D, Forenza, S, Goldfarb, R H, Matera, J et al.
DOI: 10.1093/annonc/mdy529

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

PMID: 30624616
Journal: ANNALS OF ONCOLOGY
Year: 2019
Reference: Ann Oncol. 2019 Jun 1;30(6):1017. doi: 10.1093/annonc/mdy529.
Impact factor:
Publication type: Letter or abstract
Authors: Azarnia, N; Baselga, J; Byakhov, M; Cortes, J; Forenza, S; Goldfarb, R H; Hudis, C A; Llombart, A; Lokanatha, D; Manikhas, A et al.
DOI: 10.1093/annonc/mdy529

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.

PMID: 30817251
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2019
Reference: J Clin Oncol. 2019 May 1;37(13):1051-1061. doi: 10.1200/JCO.18.02031. Epub 2019 Feb 28.
Impact factor: 28.245
Publication type: Paper in international publication
Authors: Heery, Christopher R, Gulley, James L, Borre, Michael, Vogelzang, Nicholas J, Ng, Siobhan, Agarwal, Neeraj, Parker, Chris C, Pook, David W, Rathenborg, Per, Flaig, Thomas W et al.
DOI: 10.1200/JCO.18.02031

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.

PMID: 30817251
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2019
Reference: J Clin Oncol. 2019 May 1;37(13):1051-1061. doi: 10.1200/JCO.18.02031. Epub 2019 Feb 28.
Impact factor:
Publication type: Paper in international publication
Authors: Agarwal, Neeraj; Borre, Michael; Carles, Joan; Chen, Liddy; Flaig, Thomas W; Gerritsen, Winald R; Gulley, James L; Heery, Christopher R; Kantoff, Philip W; Langkilde, Niels C et al.
DOI: 10.1200/JCO.18.02031

Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2.

PMID: 30523758
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2019
Reference: J Clin Oncol. 2019 Jan 20;37(3):230-238. doi: 10.1200/JCO.18.00089. Epub 2018 Dec 4.
Impact factor: 28.245
Publication type: Paper in international publication
Authors: Macarulla, Teresa, Pazo-Cid, Roberto, Guillen-Ponce, Carmen, Lopez, Rafael, Vera, Ruth, Reboredo, Margarita, Munoz Martin, Andres, Rivera, Fernando, Diaz Beveridge, Roberto, La Casta, Adelaida et al.
DOI: 10.1200/JCO.18.00089

Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2.

PMID: 30523758
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2019
Reference: J Clin Oncol. 2019 Jan 20;37(3):230-238. doi: 10.1200/JCO.18.00089. Epub 2018 Dec 4.
Impact factor:
Publication type: Paper in international publication
Authors: Ales, Immaculada; Diaz Beveridge, Roberto; Guillen-Ponce, Carmen; Hidalgo, Manuel; La Casta, Adelaida; Lopez, Rafael; Macarulla, Teresa; Martin Valades, Jose; Martinez-Galan, Joaquina; Munoz Martin, Andres et al.
DOI: 10.1200/JCO.18.00089

Publications

Publications searcher

Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory Small Cell Lung Cancer.

Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory Small Cell Lung Cancer.

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

Phase I study of rapid alternation of sunitinib and regorafenib for the treatment of tyrosine-kinase inhibitor refractory gastrointestinal stromal tumors.

Phase I study of rapid alternation of sunitinib and regorafenib for the treatment of tyrosine-kinase inhibitor refractory gastrointestinal stromal tumors.

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.

Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.

Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.

Phase II randomized study of radiotherapy and three-year androgen deprivation with or without concurrent weekly docetaxel in high-risk localized prostate cancer patients.

Phase II randomized study of radiotherapy and three-year androgen deprivation with or without concurrent weekly docetaxel in high-risk localized prostate cancer patients.

Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR study.

Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR study.

Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.

Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.

Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide.

Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide.

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.

Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2.

Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2.

Patronage:

Collaborating:

Accreditations: